Numinus Wellness (TSE:NUMI) has released an update.
Numinus Wellness Inc. has addressed the FDA’s refusal to approve MDMA-assisted therapy for PTSD by reiterating their commitment to advancing psychedelic therapies and continuing their pursuit of profitability through existing operations. Despite the setback, Numinus remains confident in the future efficacy of MDMA and other psychedelic treatments, and highlights their continued leadership in providing mental health care and conducting clinical research.
For further insights into TSE:NUMI stock, check out TipRanks’ Stock Analysis page.
